Related Experiment Video
Updated: Apr 25, 2026
Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
Placenta-oriented self-assembled Aspirin-RGDV nanoconjugates attenuate preeclampsia through restoration of angiogenic
Ying Zhang1, Wenqiang Qian2,1, Yao Yao2
1Research Center for Clinical Pharmacy, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Insights
A novel aspirin nanoconjugate (A-RGDV) targets the placenta, improving pre-eclampsia outcomes with reduced fetal exposure. This engineered therapy offers superior maternal-fetal benefits compared to standard aspirin prophylaxis.
Area of Science:
- Obstetrics and Gynecology
- Nanomedicine
- Pharmacology
Background:
- Pre-eclampsia (PE) is a major cause of pregnancy complications, with aspirin as the primary prophylaxis.
- Current aspirin therapy for PE has limitations in placental exposure and long-term safety.
- Developing targeted therapies is crucial for improving maternal-fetal outcomes in PE.
Purpose of the Study:
- To engineer an aspirin-RGDV nanoconjugate for targeted placental delivery and enhanced pre-eclampsia prophylaxis.
- To evaluate the safety and efficacy of A-RGDV in preclinical models of PE.
- To compare the therapeutic benefits of A-RGDV with conventional aspirin treatment.
Main Methods:
- Aspirin-RGDV tetrapeptide conjugate self-assembled into serum-stable nanostructures targeting placental integrin αV.
- In vitro assessment of hemolytic activity and cytotoxicity in trophoblast cells.
- In vivo pharmacokinetic, tissue distribution, and efficacy studies in a murine PE model (L-NAME induced).
Main Results:
- A-RGDV demonstrated negligible hemolytic activity and no cytotoxicity to trophoblast cells.
- A-RGDV significantly improved trophoblast viability and reduced apoptosis under hypoxic stress compared to aspirin.
- Pharmacokinetic studies showed prolonged plasma retention and enhanced placental accumulation (over 50-fold increase) of A-RGDV with reduced fetal exposure.
- In vivo, A-RGDV effectively attenuated hypertension, increased fetal/placental weights, and reduced resorption rates in a PE mouse model.
- A-RGDV promoted rebalanced angiogenic profiles (sFlt-1/PlGF) and corrected thromboxane/prostacyclin signaling.
Conclusions:
- A-RGDV nanoconjugates offer targeted placental protection via integrin αV guidance.
- The engineered A-RGDV provides superior maternal-fetal benefits and improved therapeutic outcomes compared to aspirin.
- A-RGDV represents a promising placenta-targeted, dose-sparing therapeutic strategy for pre-eclampsia.
Abstract:
Pre-eclampsia (PE) is a placenta-originated pregnancy disorder and a leading cause of maternal-fetal morbidity and mortality worldwide. Aspirin is the only widely recommended evidence-based prophylaxis for PE, yet its therapeutic potential is constrained by limited placental exposure and concerns with long-term dosing. To address these issues, this study engineered an aspirin-RGDV tetrapeptide conjugate (A-RGDV) that self-assembled into serum-stable nanostructures capable of selectively targeting placental integrin αV. The designed A-RGDV showed negligible hemolytic activity and no detectable cytotoxicity toward HTR-8/SVneo trophoblast cells across a concentration range of 5-200 μg/mL. Under CoCl₂ hypoxia-mimetic stress, A-RGDV improved trophoblast viability beyond equimolar aspirin and reduced total apoptosis from 34.6% (model) to 13.6%, versus 23.4% with aspirin. Pharmacokinetic studies revealed that nanoconjugates improved the in vivo behavior of aspirin, evidenced by prolonged plasma retention and an increased area under the concentration-time curve. Tissue distribution studies confirmed pronounced placental enrichment of A-RGDV, with placental drug levels increased by over 50-fold at both 2 h and 6 h compared with aspirin, while fetal exposure was markedly reduced. In an L-NAME-induced murine PE model, A-RGDV more effectively attenuated gestational hypertension than low-dose aspirin, increased fetal and placental weights, and reduced resorption rates to less than 10%. Circulating and placental angiogenic profiles trended toward rebalanced sFlt-1/PlGF, alongside correction of thromboxane/prostacyclin signaling. Collectively, A-RGDV provides integrin-guided placental protection and superior maternal-fetal benefits compared with aspirin, supporting placenta-targeted, dose-sparing therapy for PE.
More Related Videos
05:30Trophoblast Cell Recovery from Angiogenesis-Tube Formation Assay for Differentiation Marker Expression Analysis
Published on: November 8, 2024
05:31Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles
Published on: January 26, 2024
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:24Regulation of Angiogenesis and Blood Supply
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...